Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Longboard Pharmaceuticals Inc
(NQ:
LBPH
)
36.49
+1.82 (+5.25%)
Streaming Delayed Price
Updated: 3:29 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Longboard Pharmaceuticals Inc
< Previous
1
2
Next >
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 02, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 01, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
July 29, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 03, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
July 01, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
June 10, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 03, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 06, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 02, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
April 03, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 02, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
March 12, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
March 01, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 02, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February
February 01, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 08, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
This biotech stock has surged over 300% this week
January 05, 2024
Shares of Longboard Pharmaceuticals (NASDAQ: LBPH) have sky-rocketed higher this week, up over 300% thanks to breaking news
Via
MarketBeat
Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
January 03, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock
January 02, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
January 02, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
January 01, 2024
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers
November 29, 2023
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community
November 21, 2023
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2023
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 02, 2023
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November
November 01, 2023
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals Announces Speakers for Investor & Analyst Event in New York on October 11, 2023
October 05, 2023
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023
September 19, 2023
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences
August 31, 2023
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings
August 30, 2023
From
Longboard Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.